We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

By LabMedica International staff writers
Posted on 13 Mar 2024
Print article
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative disease assays. Both companies entered into a collaboration agreement in 2023 to target new biomarkers in line with the recently approved monoclonal antibody-based Alzheimer’s disease therapeutics. These new drugs have demonstrated a major impact on slowing disease progression and improving patients' health. The companies have now extended this research program and further refined the target analytes, including a pTau217 plasma assay being developed by Beckman Coulter and a Beta Amyloid 1-42 plasma assay under development by Fujirebio.

These new assays are being developed for use on the recently launched DxI 9000 Immunoassay Analyzer from Beckman Coulter. The DxI 9000 Analyzer’s novel Lumi-Phos PRO Substrate has demonstrated the ability to develop highly sensitive and clinically relevant assays. This agreement leverages Fujirebio’s expertise in the development, manufacturing and regulatory registration of its Neurological Reagent Kits and its wide Neurological Biomarker menu. Fujirebio currently offers a full range of research use only (RUO) blood-based neurodegenerative biomarkers including β-amyloid1-42, β-amyloid1-40, phospho-Tau181, neurofilament light (NfL), ApoE4, Pan-ApoE and phospho-Tau217.

“We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the bloodstream,” said Kevin O’Reilly, President, Beckman Coulter Diagnostics.

“Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world,” added Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. “We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide.”

New
Gold Member
ANCA IFA
Kallestad Autoimmune ANCA IFA Complete Kit
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Silver Member
Cytomegalovirus Test
ReQuest CMV IgM ELISA
New
Neuron-Specific Enolase ELISA
Human NSE ELISA Test Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The researchers used state-of the-art equipment for isotope ratio mass spectrometry (Photo courtesy of The University of Melbourne)

New Blood Test to Detect Alzheimer’s Disease Before Clinical Symptoms Develop

Alzheimer’s disease (AD) is the most common form of dementia, accounting for 60-70% of cases worldwide, totaling over 33 million, according to the World Health Organization. As the global population ages,... Read more

Hematology

view channel
Image: The new platelet-centric scoring system predicts platelet hyperreactivity and related risk of cardiovascular events (Photo courtesy of Shutterstock)

Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke

Platelets, which are cell fragments circulating in the blood, play a critical role in clot formation to stop bleeding. However, in some individuals, platelets can become "hyperreactive," leading to excessive... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: The Accelerate WAVE system delivers rapid AST directly from positive blood culture bottles (Photo courtesy of Accelerate Diagnostics)

Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1.32 million of these deaths directly linked... Read more

Pathology

view channel
Image: The ChatGPT-like AI model can diagnose cancer, guide treatment choice, predict survival across multiple cancer types (Photo courtesy of 123RF)

AI Tool Diagnoses Cancer, Guides Treatment and Predicts Survival Across Multiple Cancer Types

Current artificial intelligence (AI) models are typically specialized, designed for specific tasks like detecting cancer or predicting tumor genetics, and are limited to a few cancer types.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.